Storia in 2 fonti

GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes

NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 diabetes, according to data from a phase 2 trial. Zenagamtide (Novo Nordisk) is under investigation for once-weekly subcutaneous and once-daily oral administration for the treatment of type 2 diabetes and obesity. As Healio previously reported from topline results

Raccontata da

medpagetoday.com

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 mese fa

GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes

Non è possibile riassumere questo articolo per Warptech Tech News. L'articolo tratta endocrinologia/farmacologia (trial clinico di zenagamtide per type 2 diabetes) — non rientra nella topica della testata (AI, Tech, Startup, Business, Infrastructure, Cloud, etc.). Non c'è alcuna implicazione di mercato tech o di stack decisionale per manager IT/CTO. Hai l'articolo corretto da riassumere? 👀

originale

medpagetoday.com1 mese fa

Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes

Investigational pill was well-tolerated and doesn't come with food or water restrictions

Leggi questa versione →

Timeline cronologica

martedì 9 giugno 2026·medpagetoday.com
Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes
Investigational pill was well-tolerated and doesn't come with food or water restrictions
venerdì 12 giugno 2026·healio.com
GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes
NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 diabetes, according to data from a phase 2…